COMP <GO>
SRRK vs ADPT // 10Y YIELD & FRED MACRO BETA
Scholar Rock Holding Corporation (NASDAQ) VS. Adaptive Biotechnologies Corporation (NASDAQ) • 15-METRIC TALLY: SRRK 3
— ADPT 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: SRRK
LAST: $44.18 (+2.15%) • MKT CAP: $5.38B
macro-sensitivity
1.02
LAST: $28.17 (-0.70%) • MKT CAP: $4.50B
macro-sensitivity
1.01
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. ADPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRRK | ADPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -12.50% | -22.50 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.59% | -1.09% | -4.50 | ADPT | /fcf-yield <GO> |
| Operating Margin | — | -20.60% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -21.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 54.80% | -47.10 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.67 | 6.32 | +7.35 | SRRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 57.6 | -7.10 | ADPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.02 | 1.01 | +0.01 | SRRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 26.0x | +6.00 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $4.50B | $884.7M | SRRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRRK REV | ADPT REV | SRRK GROSS % | ADPT GROSS % | SRRK FCF | ADPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $277.0M | — | 74.2% | -$300.6M | -$48.9M |
| FY 2024 | $0 | $179.0M | — | 59.7% | -$201.0M | -$98.9M |
| FY 2023 | $0 | $170.3M | — | — | -$145.2M | -$164.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
ADPT // BETA 1.01